SLX-2119

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP15921CAS No. ：911417-87-3Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	911417-87-3	Cat. No.	BCP15921
Name	SLX-2119
Synonyms	SLX 2119;SLX2119;KD-025;KD 025;KD025;ROCK inhibitor;
SMILES
Chemical Name
Formula	C26H24N6O2	M. Wt	452.51
Purity	98%	Storage	Store at 4-8°C
Description	in vitro: SLx-2119 selectively inhibits activity of human ROCK2 (IC50 = 105 nM), while effects on human ROCK1 in this cell-free system were minimal (IC50 = 24 μM). SLx-2119 at 40 μM induced significant down-regulations of Tsp-1 and CTGF mRNA levels. SLx-2119 induced a significant down-regulation of Tsp-1 transcripts in HMVEC and PASMC only and induced a down-regulation of CTGF transcripts, although non-significant, in all 3 cell types(HMVEC, PASMC, and NHDF). SLx-2119 induced a down-regulation of the genes COL1A1, COL1A2, COL3A1, and COL5A2 in PASMC, an up-regulation of the gene MMP1 in PASMC, a down-regulation of the gene COL3A1 in NHDF, and an up-regulation of the genes COL7A1, COL4A2, MMP1, MMP3, MMP14, and MMP17 in NHDF. in vivo: SLX-2119 200 mg/kg twice a day for 36 h starting 1 h after ischemia onset, significantly reduced tissue loss in the ipsilateral hemisphere compared with vehicle when measured 4 weeks after ischemia.SLX-2119 appeared even more efficacious in females (42% re